JPMorgan Chase & Co. cut shares of IGM Biosciences (NASDAQ:IGMS – Free Report) from a neutral rating to an underweight rating in a research report released on Tuesday, Marketbeat reports. The brokerage currently has $9.00 target price on the stock, down from their previous target price of $12.00. Several other brokerages have also commented on […]

Truist Financial lowered shares of IGM Biosciences (NASDAQ:IGMS – Free Report) from a buy rating to a hold rating in a report released on Tuesday, Marketbeat Ratings reports. The firm currently has $12.00 price objective on the stock, down from their previous price objective of $24.00. IGMS has been the topic of several other research […]

IGM Biosciences (NASDAQ:IGMS – Free Report) had its price target decreased by Wedbush from $25.00 to $22.00 in a research report report published on Tuesday, Benzinga reports. Wedbush currently has an outperform rating on the stock. Wedbush also issued estimates for IGM Biosciences’ Q3 2024 earnings at ($0.83) EPS, Q4 2024 earnings at ($0.71) EPS, […]

IGM Biosciences (NASDAQ:IGMS – Free Report) had its price target lowered by Guggenheim from $25.00 to $20.00 in a research report sent to investors on Tuesday, Benzinga reports. Guggenheim currently has a buy rating on the stock. Other analysts have also issued reports about the stock. Truist Financial lowered shares of IGM Biosciences from a […]

IGM Biosciences (NASDAQ:IGMS – Get Free Report) was downgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating in a research note issued to investors on Tuesday, Marketbeat.com reports. They currently have a $9.00 target price on the stock, down from their previous target price of $12.00. JPMorgan Chase […]

IGM Biosciences (NASDAQ:IGMS – Get Free Report) had its target price lowered by stock analysts at Royal Bank of Canada from $20.00 to $17.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank of Canada’s price objective points to […]